<DOC>
	<DOCNO>NCT00818064</DOCNO>
	<brief_summary>This trial conduct Europe . The aim clinical trial investigate safety tolerability single dose Anti-IL-20 healthy volunteer ( HV ) patient rheumatoid arthritis ( RA ) .</brief_summary>
	<brief_title>Safety Tolerability Anti-IL-20 Healthy Volunteers Patients With Rheumatoid Arthritis</brief_title>
	<detailed_description />
	<mesh_term>Arthritis</mesh_term>
	<mesh_term>Arthritis , Rheumatoid</mesh_term>
	<mesh_term>Inflammation</mesh_term>
	<criteria>For healthy volunteer ( HV ) follow applies : Subjects consider generally healthy base assessment medical history , physical examination clinical laboratory data screening , judge Investigator Females postmenopausal , surgically sterile nonchildbearing potential For rheumatoid arthritis ( RA ) patient follow applies : A diagnosis rheumatoid arthritis accord American College Rheumatology ( ACR1987 classification ) least three month ' duration prior dose Active RA , characterise Disease Activity Score 28 ( DAS28 ) great 3.2 Methotrexate treatment ( stable dos maximally 25.0 mg/week least 4 week ) concomitant intake folic acid 1 mg/day 5 mg/week Females postmenopausal , surgically sterile nonchildbearing potential For healthy volunteer ( HV ) follow applies : Male subject accept use double barrier method birth control first dose 3 moth last visit Body mass index ( BMI ) 18.5 35.0 kg/m2 Clinically significant cardiac cardiovascular disease Abnormal blood pressure heart rate Hepatic insufficiency Renal insufficiency Positive humane immunodeficiency virus ( HIV ) Positive hepatitis B ( HBV ) hepatitis C ( HCV ) Lymphoproliferative disease History sign malignancy ( except adequately treat cured basal squamous cell carcinoma skin cervical carcinoma situ occur 12 month prior dose ) History autoimmune current inflammatory condition include rheumatoid arthritis joint disease Active latent tuberculosis : For tuberculosis unvaccinated subject detect positive Mantoux test . For subject vaccinate tuberculosis detect positive QuantiFerontest Chronic ongoing infectious disease require systemic antiinfectious treatment within last 2 week prior administration trial drug Any vaccination within last month dose Known active viral , bacterial fungal infection , include herpes , herpes zoster cold sore 14 day prior dose Use prescription nonprescription drug , include vitamin , herbal dietary supplement within 2 week prior dose , unless opinion Investigator medication interfere trial procedure compromise safety subject History current drug and/or alcohol abuse Blood donation within last 3 month ( 0.45 L ) For rheumatoid arthritis ( RA ) patient follow applies : Male subject accept use double barrier method birth control first dose 3 month last visit Body mass index ( BMI ) 18.5 35.0 kg/m2 Subjects chronic inflammatory autoimmune disease rheumatoid arthritis ( except secondary Sj√∂gren 's syndrome ) History current inflammatory joint disease rheumatoid arthritis ( e.g . gout , psoriatic reactive arthritis , Lyme 's disease , juvenile arthritis ) Chronic ongoing infectious disease require systemic antiinfectious treatment within last 2 week prior dose Any vaccination within last month dose Known active viral , bacterial fungal infection , include herpes , herpes zoster cold sore 14 day prior administration trial product Lymphoproliferative disease History sign malignancy ( except adequately treat cured basal squamous cell carcinoma skin cervical carcinoma situ occur 12 month prior dose ) Use selective cyclooxygenase2 ( COX2 ) inhibitor within last 2 week prior randomisation Concomitant medication</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>February 2017</verification_date>
</DOC>